release configuration , an API can be incorporated into the external later as well , allowing for earlier absorption once the erosion process has begun .” The OralogiK™ mechanism has also been applied to a colon targeted product , CologiK™ , which aims for a more proximal release in the lower regions of the GIT .
OralogiK™ is also playing a pivotal role in an exciting project , as Carol explains : “ We are delighted to be working so closely with our partner at Contera Pharma . What they are doing in the space of neurology and rare disease , including Parkinson ’ s disease , is really exciting .
“ During the course of Parkinson ’ s disease ( PD ), mobility problems and recurring tremor early in the morning , before the first intake of levodopa , are part of the development of motor complications associated with sustained oral levodopa treatment of PD . Recent surveys have indicated that early morning akinesia ( or morning OFF episodes ) are present in around 60 percent of PD patients across all disease stages and that a similar number of patients are affected by nocturnal immobility with difficulties turning in bed . As such , nocturnal immobility and morning akinesia are key medical unmet needs and significant contributors to impaired sleep quality and reduced quality of life for patients . There are currently no effective , reliable , and easy to use treatment options available to satisfactorily address these problems .
“ The partnership with Contera Pharma is focusing on the development of a novel tablet formulation of levodopa / carbidopa ( CP-012 ) to specifically treat
130